Congratulations to the ODYSSEY OUTCOMES team on the publication of Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome in The New England Journal of Medicine.
The ODYSSEY OUTCOMES clinical trial sought to determine whether alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome (ACS) in patients receiving high-intensity statin therapy.
The investigators conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an ACS within the previous year, had high levels of low-density lipoprotein (LDL) cholesterol, and were receiving intensive statin therapy. The trial’s primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.
The investigators concluded that, among patients 1-12 months post-ACS and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.
You can read the complete article detailing the results of this large, international, clinical trial coordinated in Canada by the Canadian VIGOUR Centre (CVC) here.
